Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston from September 9-10, 2024. Dr. Gwenn M. Hansen, the company's chief scientific officer, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform on Tuesday, September 10, from 9:05 to 9:25 a.m. ET.
The presentation, titled 'Targeted Protein Degraders As Next Generation Antibody Payloads', will showcase Nurix's innovative approach to developing targeted protein modulation drugs for cancer and inflammatory diseases. Interested parties can access the presentation slides from September 9, 2024, through the Investors section of the Nurix website under Events and Presentations.
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focusing on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA (September 5)
2. H.C. Wainwright 26th Annual Global Investment Conference in New York City (September 9)
3. Baird 2024 Global Healthcare Conference in New York City (September 10)
Key executives, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will participate in fireside chats and presentations. Most events will be webcast live and accessible through the Investors section of Nurix's website, with recordings available for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX) reported its Q2 fiscal 2024 results, highlighting significant advancements. The company showcased positive clinical data for NX-5948 at the European Hematology Association Congress, demonstrating a 69.2% objective response rate in heavily pretreated CLL patients.
Financially, Nurix strengthened its cash position to $452.5 million, largely from a $188.7 million public offering. Key leadership appointments include Dr. Paula G. O’Connor as CMO and Dr. Pasit Phiasivongsa as CTO.
Q2 collaboration revenue grew to $12.1 million from $10.7 million YoY, driven by a milestone with Pfizer. However, R&D expenses increased to $48.9 million, contributing to a net loss of $44.5 million, or ($0.71) per share.
Nurix plans to advance NX-5948 into pivotal trials in 2025, alongside other pipeline developments including NX-2127 and NX-1607.
On July 8, 2024, Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical firm focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, announced its participation in the UBS Virtual Targeted Protein Degradation (TPD) Day. Dr. Arthur T. Sands, Nurix's President and CEO, will engage in a fireside chat at 2:30 p.m. ET on July 15, 2024. The discussion will be webcast live and accessible through the Investors section of Nurix's website, under Events and Presentations, and the archived version will remain available for 30 days post-event.
Nurix Therapeutics released positive results for NX-5948 during the EHA 2024 congress. The drug, targeting relapsed/refractory CLL, showed a 69.2% objective response rate in heavily pretreated patients, including those with BTK inhibitor resistance. Responses were rapid and deepened with prolonged treatment. Adverse events were manageable, with common side effects being purpura, thrombocytopenia, and neutropenia. Based on these results, Nurix plans pivotal trials in 2025. A webcast discussing these findings will be held on June 16, 2024, at 9:00 a.m. ET.
Nurix Therapeutics (Nasdaq: NRIX) will host a webcast and conference call on June 16, 2024, at 9:00 a.m. ET to discuss data from its ongoing Phase 1 clinical trial of NX-5948. This presentation will occur in an oral session at the European Hematology Association Congress in Madrid, Spain. The Phase 1a/b study of NX-5948 focuses on heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Key points include data on patients with BTK inhibitor resistance mutations and CNS involvement. The oral presentation, titled "Latest results from an ongoing first-in-human Phase 1a/b study of NX-5948," will be presented by Dr. Kim Linton on June 16, 2024, from 11:30 a.m. to 12:45 p.m. CEST.
Nurix Therapeutics (Nasdaq: NRIX) announced that its CEO, Dr. Arthur T. Sands, will present a corporate update at the Jefferies Global Healthcare Conference. This presentation is scheduled for June 5, 2024, at 5:30 p.m. ET in New York City. The event will be webcast live, and an archived version will be available for 30 days post-event. Nurix is a clinical-stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases. The announcement highlights the company's continued efforts to engage with the medical and financial communities.
Nurix Therapeutics announced the appointments of Paula G. O’Connor, M.D., as Chief Medical Officer, and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer.
Dr. O’Connor, with over 15 years of drug development experience, joined Nurix in 2022 and has held senior positions at Protagonist Therapeutics and Genentech. Dr. Phiasivongsa, also joining in 2022, has extensive expertise in CMC development and has held leadership roles at Kronos Bio and Principia Biopharma.
These appointments aim to accelerate the development of Nurix's NX-5948 program targeting B cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
Nurix Therapeutics announced a transition in its board leadership. David L. Lacey stepped down as chair, continuing his role as a board member and committee leader. Julia P. Gregory, a current board member since 2019, was unanimously elected as the new board chair. Nurix's CEO, Arthur T. Sands, praised Lacey's guidance and expressed confidence in Gregory's ability to drive the company forward. Gregory brings extensive experience, having held leadership roles at ContraFect , Five Prime Therapeutics, and Lexicon Pharmaceuticals. The company is focused on developing targeted protein modulation drugs for cancer and inflammatory diseases.
Nurix Therapeutics will present new data on their selective BTK degrader, NX-5948, at the European Hematology Association Congress (EHA2024) from June 13-16, 2024, in Madrid, Spain, and virtually.
The data, from an ongoing Phase 1a/b study, show a 70% overall response rate in 10 heavily pretreated CLL patients with resistance mutations to BTK inhibitors. The responses are deepening with longer treatment duration, and all responses are ongoing as of January 2024.
The presentation will also include additional data at higher dose levels and longer treatment durations. Nurix will host a webcast conference call on June 16 following the presentation.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
